WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that it has priced an offering of €300 million aggregate principal amount of 0.600% Senior Notes due 2021 at an issue price of 99.950% of the principal amount.

The issuance of the notes is expected to close on April 11, 2018, subject to customary closing conditions. The notes will pay interest on an annual basis.

PerkinElmer plans to use the net proceeds of the offering to repay all of the $200 million aggregate principal amount outstanding under its term loan facility and to repay a portion of the aggregate principal amount outstanding under its revolving credit facility, in each case incurred to pay a portion of the purchase price of its acquisition of EUROIMMUN Medizinische Labordiagnostika AG, which closed on December 19, 2017. PerkinElmer expects to use any remaining proceeds for general corporate purposes.

About PerkinElmer

PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. The Company reported revenue of approximately $2.3 billion in 2017, has about 11,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index.